Lipid Growth Factor for Normal and Malignant B Cells
Lipid Growth Factor for Normal and Malignant B Cells
批准号:
6729984
负责人:
ULRICH G HAMMERLING
金额:
$23.68万
依托单位国家:
美国
项目类别:
财政年份:
1989
资助国家:
美国
项目状态:
已结题
起止时间:
1989-07-24 至 2006-03-31
关键词:
B lymphocyteapoptosisbiological signal transductioncell growth regulationchimeric proteinscytokine receptorsepidermal growth factorgrowth factorguanine nucleotide binding proteinmitogen activated protein kinasenutrition aspect of canceroncoproteinsplatelet derived growth factorprotein bindingprotein kinaserecombinant proteinsretinoid binding proteinsretinoidstissue /cell culturetransfection /expression vectortumor necrosis factor alphavitamin analogvitamin metabolism
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The pleotropic symptoms of Vitamin A deficiency include a marked immune deficiency. During the past decade our group has defined a tissue culture model, has shown that cell survival/death decisions are regulated by retinol, has identified several novel retinol metabolites important for lymphocyte survival, and has solved their structure. 14-hydroxy retro- retinol (HRR) is the prototype of agonistically acting retinoids, supporting lymphocyte survival, whereas anhydroretinol (AR) most often induces apoptosis. Both retro-retinoids can be traced fa br back in evolution to invertebrates, implying a very basic biological role. By contrast, retinoic acid is an invention of vertebrates. During the last grant period we have identified serine/threonine kinases, cRaf and PKC, as the principal receptors of retro-retinoids. Binding occurs at high affinity at the cysteine-rich domain that these kinases share in common, and bound retinol and HRR enhance the activation of phosphotransferase activity by oxidizing agents. We have formulated the working hypothesis that the cys domain functions as a retinoid-regulated redox switch. Retinoids act as catalysts to target special cysteines for selective oxidation. The proposed work will seek to identify the crucial step in the cRaf activation cycle where redox activation occurs (AIM number 1), to define the chemical changes in the oxidized cys domain, and the possible changes in redox potential created by bound retinoids (AIM number 2), and to identify the precise cysteine residues undergoing oxidation. If substantiated the new paradigm will lead to an understanding of how redox activation can be targeted effectively to signaling molecules. Redox regulation is increasingly accepted as controlling factor of immune cells in innate and adaptive immune reactions. The significance of retinoids lies in their capacity to fine-tune this redox signaling network. The marked differences in redox regulation among different retinoids, especially the capacity in AR to block redox signaling that we have demonstrated, may also allow translation into cancer therapy.
期刊论文(13)
专著(0)
科研奖励(0)
会议论文
Retinoylserine and retinoylalanine, natural products of the moth Trichoplusia ni.
视黄酰丝氨酸和视黄酰丙氨酸是Trichoplusia ni蛾的天然产物。
DOI:
10.1021/np0496791
发表时间:
2005
期刊:
Journal of natural products
影响因子:
5.1
作者:
[Rogge,Barbara, Itagaki,Yasuhiro, Fishkin,Nathan, Levi,Ester, Rühl,Ralph, Yi,San-San, Nakanishi,Koji, Hammerling,Ulrich]
通讯作者:
Hammerling,Ulrich
EGR-1, the reluctant suppression factor: EGR-1 is known to function in the regulation of growth, differentiation, and also has significant tumor suppressor activity and a mechanism involving the induction of TGF-beta1 is postulated to account for this sup
EGR-1,不情愿的抑制因子:已知 EGR-1 具有调节生长、分化的功能,并且还具有显着的肿瘤抑制活性,并且推测涉及诱导 TGF-β1 的机制可以解释这种抑制作用。
DOI:
--
发表时间:
1996
期刊:
Critical reviews in oncogenesis
影响因子:
--
作者:
[Liu,C, Calogero,A, Ragona,G, Adamson,E, Mercola,D]
通讯作者:
Mercola,D
DOI:
10.1084/jem.192.6.835
发表时间:
2000-09-18
期刊:
The Journal of experimental medicine
影响因子:
--
作者:
[Hoyos B, Imam A, Chua R, Swenson C, Tong GX, Levi E, Noy N, Hämmerling U]
通讯作者:
Hämmerling U
New Pathway of Vitamin A Action.
-
批准号:7469998
-
项目类别:
-
资助金额:$33.93万
-
财政年份:2005
-
负责人:ULRICH G HAMMERLING
-
依托单位:
New Pathway of Vitamin A Action.
-
批准号:6967756
-
项目类别:
-
资助金额:$34.76万
-
财政年份:2005
-
负责人:ULRICH G HAMMERLING
-
依托单位:
New Pathway of Vitamin A Action.
-
批准号:7122785
-
项目类别:
-
资助金额:$36.13万
-
财政年份:2005
-
负责人:ULRICH G HAMMERLING
-
依托单位:
New Pathway of Vitamin A Action.
-
批准号:7245146
-
项目类别:
-
资助金额:$34.63万
-
财政年份:2005
-
负责人:ULRICH G HAMMERLING
-
依托单位:
New Pathway of Vitamin A Action.
-
批准号:7633156
-
项目类别:
-
资助金额:$33.93万
-
财政年份:2005
-
负责人:ULRICH G HAMMERLING
-
依托单位:
NOVEL RECEPTORS OF VITAMIN A IN THE CYTOPLASM
-
批准号:6230486
-
项目类别:
-
资助金额:$33.99万
-
财政年份:2001
-
负责人:ULRICH G HAMMERLING
-
依托单位:
NOVEL RECEPTORS OF VITAMIN A IN THE CYTOPLASM
-
批准号:6710501
-
项目类别:
-
资助金额:$8.15万
-
财政年份:2001
-
负责人:ULRICH G HAMMERLING
-
依托单位:
NOVEL RECEPTORS OF VITAMIN A IN THE CYTOPLASM
-
批准号:6967564
-
项目类别:
-
资助金额:$33.05万
-
财政年份:2001
-
负责人:ULRICH G HAMMERLING
-
依托单位:
NOVEL RECEPTORS OF VITAMIN A IN THE CYTOPLASM
-
批准号:6590998
-
项目类别:
-
资助金额:$8.15万
-
财政年份:2001
-
负责人:ULRICH G HAMMERLING
-
依托单位:
NOVEL RECEPTORS OF VITAMIN A IN THE CYTOPLASM
-
批准号:7107131
-
项目类别:
-
资助金额:$31.39万
-
财政年份:2001
-
负责人:ULRICH G HAMMERLING
-
依托单位:
NOVEL RECEPTORS OF VITAMIN A IN THE CYTOPLASM
-
批准号:6495839
-
项目类别:
-
资助金额:$4.84万
-
财政年份:2001
-
负责人:ULRICH G HAMMERLING
-
依托单位:
NOVEL RECEPTORS OF VITAMIN A IN THE CYTOPLASM
-
批准号:7233945
-
项目类别:
-
资助金额:$33.34万
-
财政年份:2001
-
负责人:ULRICH G HAMMERLING
-
依托单位:
NOVEL RECEPTORS OF VITAMIN A IN THE CYTOPLASM
-
批准号:6633906
-
项目类别:
-
资助金额:$33.82万
-
财政年份:2001
-
负责人:ULRICH G HAMMERLING
-
依托单位:
NOVEL RECEPTORS OF VITAMIN A IN THE CYTOPLASM
-
批准号:6514847
-
项目类别:
-
资助金额:$33.82万
-
财政年份:2001
-
负责人:ULRICH G HAMMERLING
-
依托单位:
NOVEL RECEPTORS OF VITAMIN A IN THE CYTOPLASM
-
批准号:7417904
-
项目类别:
-
资助金额:$33.47万
-
财政年份:2001
-
负责人:ULRICH G HAMMERLING
-
依托单位:
VITAMIN A AS PRECURSOR OF INTRACELLULAR SECOND MESSENGER
-
批准号:2185059
-
项目类别:
-
资助金额:$32.64万
-
财政年份:1993
-
负责人:ULRICH G HAMMERLING
-
依托单位:
VITAMIN A AS PRECURSOR OF INTRACELLULAR SECOND MESSENGER
-
批准号:3307092
-
项目类别:
-
资助金额:$32.83万
-
财政年份:1993
-
负责人:ULRICH G HAMMERLING
-
依托单位:
VITAMIN A AS PRECURSOR OF INTRACELLULAR SECOND MESSENGER
-
批准号:2185060
-
项目类别:
-
资助金额:$33.55万
-
财政年份:1993
-
负责人:ULRICH G HAMMERLING
-
依托单位:
VITAMIN A AS PRECURSOR OF INTRACELLULAR SECOND MESSENGER
-
批准号:2185058
-
项目类别:
-
资助金额:$34.55万
-
财政年份:1993
-
负责人:ULRICH G HAMMERLING
-
依托单位:
LIPID GROWTH FACTOR FOR NORMAL AND MALIGNANT B CELLS
-
批准号:2093521
-
项目类别:
-
资助金额:$24.73万
-
财政年份:1989
-
负责人:ULRICH G HAMMERLING
-
依托单位:
国内基金
海外基金
登录
查看更多内容
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
-
批准号:LBY21H010001
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2020
-
负责人:郑绪阳
-
依托单位:
去乙酰化酶SIRT1在前体mRNA可变剪切中的作用及其生理病理效应研究
-
批准号:31970691
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2019
-
负责人:张胜萍
-
依托单位:
TM9SF4调控非小细胞肺癌细胞凋亡机制研究
-
批准号:31900527
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2019
-
负责人:孙磊
-
依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
-
批准号:81703335
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2017
-
负责人:卫高菲
-
依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
-
批准号:81670594
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2016
-
负责人:陈昊
-
依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
-
批准号:81470791
-
项目类别:面上项目
-
资助金额:73.0万元
-
批准年份:2014
-
负责人:董家鸿
-
依托单位:
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
-
批准号:81301123
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2013
-
负责人:王海莲
-
依托单位:
姜黄素与TRAIL的协同抗肿瘤机制研究
-
批准号:31101223
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2011
-
负责人:曹林
-
依托单位:
转凝蛋白通过线粒体凋亡途径致足细胞凋亡的机制研究
-
批准号:81100502
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2011
-
负责人:管娜
-
依托单位:
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
-
批准号:81101529
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2011
-
负责人:陈雪芹
-
依托单位: